Commodore Capital LP 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:05 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 4,100,000 8.700% |
1,198,184 (+41.29%) |
Filing |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,901,816 7.000% |
819,693 (+39.37%) |
Filing |
| 2023-04-24 4:05 pm Purchase |
2023-04-14 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,082,123 5.100% |
633,483 (+43.73%) |
Filing |
| 2023-02-28 4:05 pm Purchase |
2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 1,448,640 3.500% |
1,448,640 (New Position) |
Filing |